Marker Therapeutics (NASDAQ:MRKR) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a report released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $10.00 target price on the stock. HC Wainwright also issued estimates for Marker Therapeutics’ Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.54) EPS.

Several other analysts have also commented on MRKR. Wall Street Zen lowered shares of Marker Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a research note on Monday. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $10.17.

Marker Therapeutics Stock Down 2.7%

Shares of MRKR opened at $1.45 on Monday. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $5.95. The stock has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $1.22. The company has a market capitalization of $24.17 million, a PE ratio of -1.18 and a beta of 1.35.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.57. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. The firm had revenue of $1.23 million during the quarter, compared to analyst estimates of $0.72 million. As a group, equities analysts anticipate that Marker Therapeutics will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Several institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics in the third quarter valued at $25,000. Two Sigma Investments LP purchased a new stake in Marker Therapeutics during the 3rd quarter worth about $33,000. Finally, Jane Street Group LLC acquired a new stake in Marker Therapeutics in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.